<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36261455</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy.</ArticleTitle><Pagination><StartPage>17443</StartPage><MedlinePgn>17443</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17443</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-22322-w</ELocationID><Abstract><AbstractText>This study aimed to develop a functional measurement that combines quantitative motor evaluation index of various body regions in patients with spinal and bulbar muscular atrophy (SBMA). We assessed subjects with SBMA and healthy controls with quantitative muscle strength measurements and functional scales. We selected tongue pressure, grip power, % peak expiratory flow (%PEF), timed walking test, and % forced vital capacity (%FVC) as components. By combining these values with Z-score, we created a functional composite (SBMA functional composite: SBMAFC). We also calculated the standardized response mean to compare the sensitivity of SBMAFC with that of existing measurements. A total of 97 genetically confirmed patients with SBMA and 36 age- and sex-matched healthy controls were enrolled. In the longitudinal analysis, the standardized response mean of SBMAFC was larger than that of existing rating scales. Receiver operating characteristic (ROC) analysis demonstrated that the SBMAFC is capable of distinguishing between subjects with early-stage SBMA and healthy controls. SBMAFC is more sensitive to disease progression than existing functional rating scales and is a potential outcome measure in clinical trials of SBMA.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Inagaki</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. hassy0707@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. hassy0707@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirakawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. ka2no@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan. ka2no@med.nagoya-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014059" MajorTopicYN="N">Tongue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36261455</ArticleId><ArticleId IdType="pmc">PMC9581920</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-22322-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-22322-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex linked recessive trait. Neurology. 1968;18:671&#x2013;680. doi: 10.1212/WNL.18.7.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR. Androgen receptor gene mutation in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2013;79. doi: 10.1038/352077a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/352077a0</ArticleId><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr CR. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J. Boil. Chem. 2010;285:35567&#x2013;35577. doi: 10.1074/jbc.M110.146845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.146845</ArticleId><ArticleId IdType="pmc">PMC2975181</ArticleId><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman AP. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7:774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA) Exp. Neurol. 2006;200:8&#x2013;18. doi: 10.1016/j.expneurol.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2006.01.021</ArticleId><ArticleId IdType="pubmed">16513111</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. Brain. 2006;129:1446&#x2013;1455. doi: 10.1093/brain/awl096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Fischbeck KH, Pennuto M, et al. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA) J. Neurol. Neurosurg. Psychiatry. 2020;91:1085&#x2013;1091. doi: 10.1136/jnnp-2020-322949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322949</ArticleId><ArticleId IdType="pubmed">32934110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et al. A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromuscul. Disord. 2015;25:554&#x2013;562. doi: 10.1016/j.nmd.2015.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.03.008</ArticleId><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 2012;135:2838&#x2013;2848. doi: 10.1093/brain/aws170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws170</ArticleId><ArticleId IdType="pubmed">22773541</ArticleId></ArticleIdList></Reference><Reference><Citation>The ALS CNTF treatment study (ACTS) phase I-II Study Group The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch. Neurol. 1996;53:141&#x2013;147. doi: 10.1001/archneur.1996.00550020045014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1996.00550020045014</ArticleId><ArticleId IdType="pubmed">8639063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohashi Y, Tashiro K, Itoyama Y, et al. Study of functional rating scale for amyotrophic lateral sclerosis: Revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei. 2001;53:346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11360474</ArticleId></ArticleIdList></Reference><Reference><Citation>Mano T, Katsuno M, Banno H, et al. Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy. Neurology. 2014;82:255&#x2013;262. doi: 10.1212/WNL.0000000000000041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000041</ArticleId><ArticleId IdType="pubmed">24353334</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto N, Yamashita T, Sato K, et al. Assessment of swallowing in motor neuron disease and Asidan/SCA36 patients with new methods. J. Neurol. Sci. 2013;324:149&#x2013;155. doi: 10.1016/j.jns.2012.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2012.10.025</ArticleId><ArticleId IdType="pubmed">23146615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mano T, Katsuno M, Banno H, et al. Head Lift Exercise Improves Swallowing Dysfunction in Spinal and Bulbar Muscular Atrophy. Eur. Neurol. 2015;74:251&#x2013;258. doi: 10.1159/000431088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000431088</ArticleId><ArticleId IdType="pubmed">26624487</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann JR, Andres P, Mendoza M, et al. Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials. J. Neurol. Sci. 1997;147:97&#x2013;111. doi: 10.1016/S0022-510X(96)05220-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(96)05220-3</ArticleId><ArticleId IdType="pubmed">9094067</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, et al. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019;92:e461&#x2013;e474. doi: 10.1212/WNL.0000000000006858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006858</ArticleId><ArticleId IdType="pmc">PMC6369904</ArticleId><ArticleId IdType="pubmed">30626655</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Katsuno M, Banno H, et al. The profile of motor unit number estimation (MUNE) in spinal and bulbar muscular atrophy. J. Neurol. Neurosurg. Psychiatry. 2010;81:567&#x2013;571. doi: 10.1136/jnnp.2009.190462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.190462</ArticleId><ArticleId IdType="pubmed">19965845</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris-Love MO, Fernandez-Rhodes L, Joe G, et al. Assessing function and endurance in adults with spinal and bulbar muscular atrophy: Validity of the adult myopathy assessment tool. Rehabil. Res. Pract. 2014;2014:873872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026974</ArticleId><ArticleId IdType="pubmed">24876969</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann. Neurol. 2009;65:140&#x2013;150. doi: 10.1002/ana.21540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21540</ArticleId><ArticleId IdType="pubmed">19259967</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi Y, Katsuno M, Banno H, et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. 2008;38:964&#x2013;971. doi: 10.1002/mus.21077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21077</ArticleId><ArticleId IdType="pubmed">18642379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, et al. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009;132:3242&#x2013;3251. doi: 10.1093/brain/awp258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp258</ArticleId><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijbels D, Dalgas U, Romberg A, et al. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult. Scler. 2012;18:364&#x2013;371. doi: 10.1177/1352458511420598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458511420598</ArticleId><ArticleId IdType="pubmed">21952098</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, D'Ascenzo C, Peterle E, et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology. 2013;80:2095&#x2013;2098. doi: 10.1212/WNL.0b013e318295d766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318295d766</ArticleId><ArticleId IdType="pubmed">23645595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, et al. Treatment with creatine monohydrate in spinal and bulbar muscular atrophy: Protocol for a randomized, double-blind placebo-controlled trial. JMIR Res. Protoc. 2018;7(3):69. doi: 10.2196/resprot.8655.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/resprot.8655</ArticleId><ArticleId IdType="pmc">PMC5859194</ArticleId><ArticleId IdType="pubmed">29506970</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, et al. Decreased peak expiratory flow associated with muscle fiber-type switching in spinal and bulbar muscular atrophy. PLoS ONE. 2016;11:e0168846. doi: 10.1371/journal.pone.0168846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168846</ArticleId><ArticleId IdType="pmc">PMC5179045</ArticleId><ArticleId IdType="pubmed">28005993</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin ED, Cournand A, Richards DW., Jr Pulmonary insufficiency; Physiological classification, clinical methods of analysis, standard values in normal subjects. Medicine. 1948;27:243&#x2013;278. doi: 10.1097/00005792-194809000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-194809000-00001</ArticleId><ArticleId IdType="pubmed">18885031</ArticleId></ArticleIdList></Reference><Reference><Citation>Berglund E, Birath G, Bjure J, Grimby G, Kjellmer I, Sandqvist L, et al. Spirometric studies in normal subjects. I Forced expirograms in subjects between 7 and 70 years of age. Acta Med. Scand. 1963;173:185&#x2013;192. doi: 10.1111/j.0954-6820.1963.tb16520.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0954-6820.1963.tb16520.x</ArticleId><ArticleId IdType="pubmed">13970718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med. Care. 1989;27(3 Suppl.):S178&#x2013;S189. doi: 10.1097/00005650-198903001-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-198903001-00015</ArticleId><ArticleId IdType="pubmed">2646488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software &#x2018;EZR&#x2019; for medical statistics. Bone Marrow Transplant. 2013;48:452&#x2013;458. doi: 10.1038/bmt.2012.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2012.244</ArticleId><ArticleId IdType="pmc">PMC3590441</ArticleId><ArticleId IdType="pubmed">23208313</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): A multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:875&#x2013;884. doi: 10.1016/S1474-4422(10)70182-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70182-4</ArticleId><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Rhodes LE, Kokkinis AD, White MJ, et al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscandomizedular atrophy: A randomized placebo-controlled trial. Lancet Neurol. 2011;10:140&#x2013;147. doi: 10.1016/S1474-4422(10)70321-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70321-5</ArticleId><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, Hirakawa A, Hijikata Y, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: Natural history-controlled study. J. Neurol. Neurosurg. Psychiatry. 2017;88:1026&#x2013;1032. doi: 10.1136/jnnp-2017-316015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316015</ArticleId><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz-H&#xfc;bsch T, du Montcel ST, et al. Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology. 2006;66:1717&#x2013;1720. doi: 10.1212/01.wnl.0000219042.60538.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000219042.60538.92</ArticleId><ArticleId IdType="pubmed">16769946</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Banno H, et al. Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. J. Neurol. 2012;259:712&#x2013;719. doi: 10.1007/s00415-011-6251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6251-2</ArticleId><ArticleId IdType="pubmed">21952871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): An integrated approach to MS clinical outcome assessment. Mult. Scler.J. 1999;5:244&#x2013;250. doi: 10.1177/135245859900500409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859900500409</ArticleId><ArticleId IdType="pubmed">10467383</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. doi: 10.1186/1471-2377-14-58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-14-58</ArticleId><ArticleId IdType="pmc">PMC3986942</ArticleId><ArticleId IdType="pubmed">24666846</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87:1985&#x2013;1992. doi: 10.1212/WNL.0000000000003319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003319</ArticleId><ArticleId IdType="pmc">PMC5109953</ArticleId><ArticleId IdType="pubmed">27733571</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz-H&#xfc;bsch T, Giunti P, Stephenson DA, Globas C, Baliko L, Sacc&#xe0; F, et al. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia. Neurology. 2008;71:486&#x2013;492. doi: 10.1212/01.wnl.0000324863.76290.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000324863.76290.19</ArticleId><ArticleId IdType="pubmed">18695159</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Montcel ST, Charles P, Ribai P, Goizet C, Le Bayon A, Labauge P, et al. Composite cerebellar functional severity score: Validation of a quantitative score of cerebellar impairment. Brain. 2008;131:1352&#x2013;1361. doi: 10.1093/brain/awn059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn059</ArticleId><ArticleId IdType="pubmed">18378516</ArticleId></ArticleIdList></Reference><Reference><Citation>Saute JA, Rieder CR, Castilhos RM, Monte TL, Schumacher-Schuh AF, Donis KC, et al. Planning future clinical trials in Machado Joseph disease: Lessons from a phase 2 trial. J. Neurol. Sci. 2015;358:72&#x2013;76. doi: 10.1016/j.jns.2015.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.08.019</ArticleId><ArticleId IdType="pubmed">26297649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N. Engl. J. Med. 2012;367:795&#x2013;804. doi: 10.1056/NEJMoa1202753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi H, Reetz K, du Montcel ST, Bauer P, Mariotti C, Nanetti L, et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: Analysis of baseline data. Lancet Neurol. 2013;12:650&#x2013;658. doi: 10.1016/S1474-4422(13)70104-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70104-2</ArticleId><ArticleId IdType="pubmed">23707147</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington&#x2019;s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12:637&#x2013;649. doi: 10.1016/S1474-4422(13)70088-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70088-7</ArticleId><ArticleId IdType="pubmed">23664844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E, Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis. Lancet Neurol. 2015;14:253&#x2013;262. doi: 10.1016/S1474-4422(14)70324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>